Identifying Influential Prognostic Factors of Death Hazard Rates in Patients with Chronic Kidney Disease (CKD) Using Weibull Model with Non-Constant Shape Parameter

Seyede Solmaz Taheri¹, Ahmadreza Baghestani²*, Farzanehsadat Minoo³, Anahita Saeedi⁴

¹Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
²Biostatistics Department, Physiotherapy Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³Center of Excellence in Nephrology, Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
⁴University of Massachusetts, School of Public Health & Health Sciences, Department of Biostatistics, Amhers, MA, USA.

INTRODUCTION: Chronic Kidney Disease (CKD) is a disease in which damaged kidneys could not remove waste material from the blood which could result in other health problems. The aim of this analysis was to identify significant laboratory prognostic factors on death hazard due to CKD.

METHODS: There were 109 patients with end-stage renal disease (ESRD) treated at Helal pharmaceutical and clinical complex. The survival time was set as the time interval from starting dialysis until death due to CKD. Age, gender and factors such as creatinine, cholesterol, uric acid, SGOT, SGPT, bilirubin, hemoglobin, potassium, ALP, HbA1C, ferritin, calcium, phosphorus, PTH and albumin were employed in this study. Weibull Distribution with non-Constant Shape Parameter versus constant Shape Parameter for the analysis were used.

RESULTS: Death due to CKD occurred in 29 (26.6%) of the patients. Sixty-seven (61.5%) had uric acid higher than 6.8 (mg/dl) and 39(35%) had phosphorus higher than 4.7 (mg/dl) which were poor prognoses. The incidence of death was 48.4%. Calcium<8.5 (mg/dl) (p=0.002), Calcium > 9.5 (mg/dl) (p=0.003), Albumin 4-6.3 (g/dl) (p=0.034), Phosphorus (p=0.022), hemoglobin<10 (g/dl) (p=0.043), hemoglobin>12.5 (g/dl) (p=0.006) and iPTH (p<0.001) were significant variables which had an effect on death hazard rates.

CONCLUSION: The Weibull model with Non-Constant shape parameter was suggested to be more accurate for identifying risk factors, leading to more precise results, compared to constant shape parameter. Investigators mostly emphasize on the importance of Calcium, Albumin, Phosphorus, hemoglobin and iPTH for reducing hazard rates in CKD patients.
which could result in other health problems such as heart disease and high blood pressure.\textsuperscript{3} Because of marked changes in bone mineral metabolism, diseases such as cardiovascular and high blood pressure, risk for fractures and overall mortality increases, as a result of damaged kidney function.\textsuperscript{4} Although CKD does not appear to be symptomatic in its early stages, the prevalence is estimated to be around 10\% to 14\% in the world.\textsuperscript{5} It has been estimated that more than 500 million people have CKD which 80\% of them are living in the less developed countries.\textsuperscript{6} Globally, the incidence of CKD increased significantly in the last three decades and it has escalated about 1.3 times from 1990 to 2016.\textsuperscript{7} In Iran, prevalence of CKD was increased from 208 (per 10,000) in 2012 to 15.4\% in 2018 in higher rate in females compared to males.\textsuperscript{8, 9} Worldwide, the deaths rate from CKD was 11.47 in 1990 and 16.05 in 2016; indicating increasing slope in mortality rate during these 27 years.\textsuperscript{7} In Iran, based on the Global Burden of Disease (GBD) the mortality rate of this disease has doubled.\textsuperscript{10, 11} There is no estimation for survival of CKD patients in Iran. In addition to dialysis and transplantation as main approaches for treatment, increasing awareness of the factors affecting the mortality rate by using valid statistical methods can be beneficial.\textsuperscript{12-14} In medical studies, the survival analysis is the analysis of time until certain events occur (such as death due to CKD) and it aims to identify hazard rates of these certain events.\textsuperscript{15} Survival time is non-negative which has often a skew distribution and Weibull distribution is generally used in survival time models because it is is very flexible and by changing its parameters, it can be used for survival times that have left or right skewness.\textsuperscript{16, 17} Among the various models applied in survival analysis, given the assumptions are met, parametric models lead to more accurate results. Weibull distribution as one of the most important parametric models requires the proportional hazard assumption (PH), in which the shape parameter should be considered constant. However, in some cases that the hazard rate is time dependent, the PH assumption is not established. In these cases, considering that the constant shape parameter leads to distorted results, non-constant shape parameter can lead to better estimation of the results.\textsuperscript{18, 19} Regarding these points and the increasing trend of CKD incidence in Iran and worldwide, the aim of this study was to determine the prognostic factors on the risk of death in patients with CKD using the Weibull parametric model with unstable shape parameter.

**Material and Methods**

In this retrospective cohort study, a total of 109 hemodialysis patients were enrolled and registered in the Iran Helal pharmaceutical and clinical complex during 2014-2018. Data were collected from hospital medical records which includes all CKD patients that were given hemodialysis three times a week. The survival time was calculated as the time interval between the time of starting dialysis and time of death due to CKD. The inclusion criteria were men and non-lactating women with negative serum pregnancy test at Screening and CKD with eGFR <60 mL/min at Screening using the 4-variable Modification of Diet in Renal Disease (MDRD) equation (with a limit of up to 20\% of the target randomization of 230 subjects with eGFR <15 mL/min). The exclusion criteria were evidence of acute kidney injury or requirement for dialysis within 12 weeks.
prior to screening, scheduled kidney transplant or initiation of dialysis planned within 24
weeks of screening, active infection requiring antibiotics at screening and malignancy. The
information of all participants in the study was confidential and subjects (or their parents or
guardians) have given their written informed consent. Also all the research was conducted
ethically in accordance with the World Medical Association Declaration of Helsinki. The
study was confirmed by the ethical committee of Shahid Beheshti University of Medical
Sciences, Tehran, Iran with the approval code is IR.SBMU.RETECH.REC.1398.789. Initially,
information on demographics was collected. A blood sample was taken after 12–14 h
overnight fasting and was centrifuged within 30–45 min of collection. All blood analyses
were performed at the research laboratory on the day of blood collection. For oral glucose
tolerance test, 82.5 g glucose monohydrate solution (equivalent to 75 g anhydrous glucose)
was administered orally to subjects and a blood sample was taken 2 hours later. Total cholesterol
(TC) and triglycerides (TG) were assayed using the enzymatic calorimetric method
with cholesterol esterase- cholesterol oxidase and glycerol phosphate oxidase, respectively.
Serum creatinine (CR) levels were assayed by kinetic colorimetric Jaffe. The sensitivity
of the assay was 0.2 mg/dL (range, 18–1330 µmol/L (0.2–15 mg/dL). Reference intervals
according to manufacturer’s recommendation were 53–97 µmol/L (0.6–1.1 mg/dL) and 80–
115 µmol/L (0.9–1.3 mg/dL) in women and men respectively. All biochemical assays were
performed using commercial kits (Pars Azmoon Inc, Tehran, Iran) by a Selectra 2 auto analyzer
(Vital Scientific, Spankeren, The Netherlands). The risk factors which were assessed in the
current analysis were age at diagnosis (years), gender, creatinine (mg/dl), cholesterol (mg/dl),
uric acid (mg/dl), serum glutamic oxaloacetic transaminase (SGOT) (U/L), serum glutamic-
pyruvic transaminase (SGPT) (U/L), bilirubin (mg/dl), hemoglobin (g/dl), potassium
(mEq/L), Alkaline phosphatase (ALP) (U/L), hemoglobin A1c (HbA1C) (mmol/mol),
ferritin (ng/ml), calcium (mg/dl), phosphorus (mg/dl), Parathyroid hormone (PTH) (pg/dl)
and albumin (g/dl).
Descriptive statistics mean (SD) for continuous variables and frequency (percentage) for
categorical factors were used to summarize demographic and prognostic variables of the
study population. In this paper, we used the model with constant and non-constant shape
parameter and then we chose the best model according to Akaike information criterion
(AIC). For data analysis, clinical, pathological and biological characteristics of patients were
evaluated in the survival model. A Weibull distribution was proposed for survival time.
The statistical analyses were carried out using SAS (SAS Institute Inc, Cary, NC, USA). SAS
codes are available upon request. The level of significance was set at $P \leq 0.05$. Weibull
distribution has two parameters, shape ($\alpha$) and location ($\beta$), which can be defined as

$$
\beta = \exp(b_0 + \sum_{j=1}^{p} b_j x_j)
$$
and

$$
\alpha = \exp(a_0 + \sum_{j=1}^{p} a_j x_j)
$$

and has a density and hazard functions as

$$
f(t|\alpha, \beta) = \alpha \beta t^{\alpha-1} \exp(-\beta t^\alpha); t > 0, \alpha > 0, \beta > 0
$$
and

$$
h(t|\alpha, \beta) = \alpha \beta t^{\alpha-1}.
$$
In this distribution, if $\alpha>1$, the risk function is incremental, if $\alpha<1$ decreasing, and if $\alpha=1$, the risk is constant, in which case the distribution becomes exponential. We can get hazard rate of any two different levels of covariates by

$$HR = \frac{h(t|x)}{h(t|x')}$$

A key point is that in Weibull distribution with non-constant shape parameter HR will not be constant over time.

**Results**

Overall, 26.6% of the patients experienced death due to CKD and others were censored. Out of 109 hemodialysis patients 71.6% were male, 33.9% had hemoglobin lower than 10 (g/dl) and 88.1% of patients had HbA1C less than 7 (mmol/mol) with mean age of 57.80 years (Table1). We explored the property of Weibull model by plotting the log {\{-log (survival probability)\}} against log (time). It shows that our dataset satisfies the Weibull distribution because all the points allies on a line (Figure1). Kaplan Meier survival curve of total population shows that the survival rate decreases over time (Figure 2). Therefore, it is wise to find time dependent covariates. The AIC of Weibull distribution with Constant Shape Parameter was 255.2 and AIC of Weibull distribution with non-Constant Shape Parameter was 186.7 (Tables 1 and 2), so Weibull distribution with non-Constant Shape Parameter is the superior model. Scale parameters which were significant based on Weibull distribution with non-Constant Shape Parameter, were calcium less than 8.5 (mg/dl) compared with 8.5-9.5 (mg/dl) (p=0.002), Albumin 4-6.3 (g/dl) compared to less than 4 (g/dl) (p=0.034) and Phosphorus (p=0.022) (Table 2). Significant parameters based on Weibull distribution with non-Constant Shape, were hemoglobin less than 10 (g/dl) compared to 10-12.5 (g/dl) (p=0.043) and hemoglobin more than 12.5 (g/dl) compared with 10-12.5 (g/dl) (p=0.006), calcium more than 9.5 (mg/dl) compared with 8.5-9.5 (mg/dl) (p=0.003), and iPTH (p<0.001) (Table 2). Based on significant prognostic factors, the fitted hazard function according to our superior model (Weibull distribution with non-Constant Shape Parameter) would be:

For instance, hazard ratio for calcium>9.5
Table 1. Identified Risk Factors of death hazard rates Based on Weibull Distribution with Constant Shape Parameter and Demographic and prognostic factors of the study population.

| Variables                  | Constant Shape and scale Parameters model$^1$ | Frequency (%) |
|----------------------------|-----------------------------------------------|---------------|
|                            | Categories                                    | Estimates parameters | P-value   |
| $\alpha$                   | $a$                                           | 4.375          | 0.0002$^*$|
| $\beta$                    | $b$                                           | -6.926         | 0.620     |
| Gender                     | Male                                          | 6.997          | 0.017$^*$ |
|                            | Female$^a$                                    | -              | -         |
| Hemoglobin (g/dl)          | $<10$                                         | 7.765          | 0.014$^*$ |
|                            | $>12.5$                                       | -1.763         | 0.483     |
|                            | 10-12.5$^a$                                   | -              | -         |
| Potassium (mEq/L)          | $>5$                                          | -0.705         | 0.455     |
|                            | 3.5-5$^a$                                     | -              | -         |
| Alkaline phosphatase (U/L) | $>300$                                        | -4.413         | 0.052     |
|                            | $<300^a$                                      | -              | -         |
| HbA1C (mmol/mol)           | $>7$                                          | 5.848          | 0.007$^*$ |
|                            | $<7^a$                                        | -              | -         |
| Calcium(mg/dl)             | $<8.5$                                        | -1.821         | 0.560     |
|                            | $>9.5$                                        | 7.036          | 0.044$^*$ |
|                            | 8.5-9.5$^a$                                   | -              | -         |
| Albumin (g/dl)             | 4-6.3                                         | 4.973          | 0.093     |
|                            | $<4^a$                                        | -              | -         |
| Age (year)                 |                                               | 0.179          | 0.003$^*$ |
| Ferritin (ng/ml)           |                                               | 0.002          | 0.113     |
| Creatinine(mg/dl)          |                                               | 0.118          | 0.110     |
| Cholesterol (mg/dl)        |                                               | -0.066         | 0.089     |
| Uric acid (mg/dl)          |                                               | -3.610         | 0.005$^*$ |
| SGOT (U/L)                 |                                               | -0.981         | 0.030$^*$ |
| SGPT (U/L)                 |                                               | 0.466          | 0.041$^*$ |
| Bilirubin (mg/dl)          |                                               | -4.689         | 0.665     |
| Phosphorus (mg/dl)         |                                               | -0.815         | 0.168     |
| Parathyroid hormone (pg/dl)|                                               | -0.008         | 0.018$^*$ |

$^a$References category
$^*$Significant at 0.05
$^5$ AIC: 255.2

SGOT, Serum glutamic oxaloacetic transaminase
SGPT, Serum glutamic-pyruvic transaminase
Table 2. Identified Risk Factors of death hazard rates Based on Weibull Distribution with Non Constant Shape Parameter Model of 109 Cases of Chronic Kidney Disease

| Variables | Categories | Estimates parameters | P-value |
|-----------|------------|----------------------|---------|
| $a_0$     | -          | -39.875              | 0.896   |
| $\alpha$  | Gender     | Male                 | 0.331   | 0.523   |
|           |            | Female               | -       | -       |
|           | Hemoglobin (g/dl) | <10           | 0.301   | 0.043*  |
|           |            | >12.5                | -0.550  | 0.006*  |
|           |            | 10-12.5*             | -       | -       |
|           | Calcium (mg/dl) | <8.5            | -0.183  | 0.414   |
|           |            | >9.5                 | 0.625   | 0.003*  |
|           |            | 8.5-9.5*             | -       | -       |
|           | iPTH (pg/dl) | 0.0004              | <0.001* | 0.052   |
| $b_0$     | Gender     | Male                 | 1.627   | 0.396   |
|           |            | Female               | -       | -       |
|           | Hemoglobin (g/dl) | <10           | 0.094   | 0.995   |
|           |            | >12.5                | 17.834  | 0.130   |
|           |            | 10-12.5*             | -       | -       |
|           | Potassium (mEq/L) | >5              | -0.015  | 0.717   |
|           |            | 3.5-5*               | -       | -       |
|           | Alkaline phosphatase (U/L) | >300     | -7.042  | 0.625   |
|           |            | <300*                | -       | -       |
|           | HbA1C (mmol/mol) | >7              | 27.033  | 0.525   |
|           |            | <7*                  | -       | -       |
|           | Calcium(mg/dl) | <8.5            | -80.819 | 0.002*  |
|           |            | >9.5                 | 6.208   | 0.762   |
|           |            | 8.5-9.5*             | -       | -       |
|           | Albumin (g/dl) | 4-6.3            | -8.353  | 0.034*  |
|           |            | <4*                  | -       | -       |
|           | Age (year)  |                      | 1.439   | 0.184   |
|           | Ferritin (ng/ml) |            | 30.638  | 0.699   |
|           | Creatinine(mg/dl) |          | -0.355  | 0.704   |
|           | Cholesterol (mg/dl) |       | -7.871  | 0.191   |
|           | Uric acid (mg/dl) |           | -2.186  | 0.503   |
|           | SGOT (U/L)  | -                    | -0.375  | 0.828   |
|           | SGPT (U/L)  | -                    | -57.339 | 0.545   |
|           | Bilirubin(mg/dl) | -           | -31.107 | 0.480   |
|           | Phosphorus (mg/dl) | -       | -0.096  | 0.022*  |
|           | Parathyroid hormone (pg/dl) | - | -12.897 | 0.270   |

*References category
'Significant at 0.05
$AIC$: 255.2

SGOT, Serum glutamic oxaloacetic transaminase
SGPT, Serum glutamic-pyruvic transaminase
Figure 1. The log{-log(survival probability)}

Figure 2. The survival curve (Kaplan Meier) of total population

compared to calcium<8.5 is:

\[
HR = \frac{h(t|x)}{h(t|x')} = \frac{\exp \left\{ 0.30(Hemoglobin < 10) - .55(Hemoglobin > 12.5) + 0.62(1) + 0.0004(\text{iPTH}) + 6.208(1) - 8.35(\text{Albumin}) - 0.09(\text{Phosphorus}) \right\}}{\exp \left\{ 0.30(Hemoglobin < 10) - .55(Hemoglobin > 12.5) - .18(1) + 0.0004(\text{iPTH}) - 80.81(1) - 8.35(\text{Albumin}) - 0.09(\text{Phosphorus}) \right\}}
\]

\[= e^{87.80 t_{87.01}} \]
It is clear that adjusted HR for calcium>9.5 (mg/dl) compared to calcium<8.5 (mg/dl) is not constant and it increases over time. Hence, according to the results, it is observed that the hazard ratio of calcium, hemoglobin and iPTH is not constant over time. Adjusted HR for hemoglobin<10 (g/dl) compared to hemoglobin>12.5 (g/dl) increases in time. In addition, adjusted HR of iPTH increases in the course of time. On the other hand, the hazard ratio of phosphorus and albumin is constant over time. Adjusted HR of phosphorus and albumin is 0.90 and 0.0002, respectively. So mortality hazard increases as phosphorus and albumin increase.

**Discussion**

In survival studies, the outcome variable is time until the event occurs. Due to the asymmetry and censorship in survival data, special analysis procedures of statistical methods are required. Weibull model as a flexible function is very advantageous in survival studies.\(^{20}\) In using the shape parameters, it is important to bear in mind that it is not always constant. The aim of the present research is to show the superiority of non-constant shape parameter against constant shape model in CKD data. Many similar studies were performed using the Weibull model with the unstable shape parameter and have shown that this model is more accurate in estimating the coefficients.\(^{21,22}\) Some authors through a simulation study, demonstrated that models with stochastic effects and unstable parameters provide a more accurate fit.\(^{23,24}\) In our study and based on Weibull distribution with non-Constant Shape Parameter, Calcium, Albumin, Phosphorus, hemoglobin and iPTH are factors that are associated with hazard death rates. Floege et al.\(^{25}\) also reported that iPTH, Calcium and Phosphorus are factors that are associated with mortality rate of haemodialysis patients. Naves-Díaz et al.\(^{26}\) who conducted a study on a large number of haemodialysis patients, reported that reduced serum levels of Albumin, Calcium, Phosphorus and PTH were associated with increments in mortality. Although, no parametric survival analysis methods were applied in their study, but the use of a large sample size made the results very accurate. In our study, despite the small sample size, we were able to extract relatively similar results with high accuracy using the correct model except calcium. Increments in mortality by a decrease in calcium level is in contrast with our study. In our research, the mortality rate for Calcium>9.5 (mg/dl) compared to Calcium<8.5 (mg/dl) increases over time. Tentori et al. used adjusted hazard ratio models and reported the highest risk of mortality for calcium or CaAlb levels greater than 10.0 (mg/dL), phosphorus levels greater than 7.0 (mg/dL), and PTH levels greater than 600 (pg/dL).\(^{27}\) Additionally, in some studies from the USA, it was found that higher levels of iPTH, Calcium and Phosphorus were associated with an increased risk of mortality.\(^{28-30}\) Cox models have been used in most studies on the survival of CKD patients, in which the main assumption is that the hazard ratio is constant over time. However, the results of the present study indicate that the hazard ratio in Calcium, iPTH and hemoglobin is not constant over time. Therefore, it is necessary to be careful in interpreting the results obtained from these models and to select appropriate models (smaller AIC). According to the results of the previous studies, if patients were diagnosed with these risk factors, it would be beneficial...
to treat them with conservative treatment. Some authors reported that low calcium level could reduce all mortality causes, while others found that increased risk of mortality is associated with low serum Calcium levels. High serum Calcium level has a negative effect on cardiovascular system and mortality. Consequently, one of the reasons for the relationship between Calcium and mortality in CKD patients is due to cardiovascular diseases. An important point from our study results is that the risk of death increases over time in patients whose calcium is higher than 9.5 (mg/dl). One scientific justification for this important finding could be the increase in calcium deposition in the arteries. Given that other factors such as hypertension, cardiovascular diseases, and malnutrition can also cause death in CKD patients. Designing extensive studies to record and review the complete data on these patients and using competing risk models seems essential. It is also necessary to design clinical trials with several groups in order to evaluate different treatments along with dialysis and evaluate their survival using more accurate models. Other studies also declared that high serum phosphorus was associated with a higher risk of mortality and reducing serum phosphorus with phosphate binders could decreases HR. Aligned results have not been reported in various studies regarding the effect of iPTH on mortality in CKD patients. The mortality due to CKD or cardiovascular diseases is a subject which requires closer examination. Based on the results of this research, further studies about iPTH on the effect of time on increasing the risk of mortality seem necessary. Ultimately, we found that adjusted HR for Calcium>9.5 (mg/dl) compared to Calcium<8.5 (mg/dl) increases over time. Our study indicated that adjusted HR for hemoglobin<10 (g/dl) compared to hemoglobin>12.5 (g/dl) increases over time. The adjusted HR of iPTH also escalates over the course of time. Moreover, we demonstrated that, the hazard ratio of phosphorus and albumin is constant over time and death hazard increases by an increase in phosphorus and albumin level. Although, the results of this study signifies the appropriateness of Weibull model with Non-Constant shape parameter compared to the Weibull model with Constant shape parameter, more studies are needed with larger sample sizes and wider variables for reaching accurate conclusions.

Limitations

One of the limitations of our study is its retrospective and observational nature. In addition, unmeasured confounding variables could increase or decrease the HR for mortalities and/or hospitalization. Small sample size which could have reduced the power of test was another limitation but it seems that with correct model we could reduce small dataset effect.

Acknowledgement

This study is related to the project number 1398.10570 From Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. We appreciate the “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences for their financial support of this study. We also appreciate Dr Seyed-Saeed Hashemi-Nazari (assistant Professor in
Department of Epidemiology of Shahid beheshti university of medical science) who linked us to the Helal pharmaceutical and clinical complex. We also appreciate the help of the Iran Helal pharmaceutical and clinical complex that provided the information needed for this research.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare regarding the publication of this article.

**Funding Sources**

This study is related to the project NO. 1398.10570 From Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. We appreciate the “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences for their financial support of this study.

**Author Contribution**

Seyede Solmaz Taheri and Ahmadreza Baghestani wrote the article and programs in SAS and data analyzing. Farzanehsadat Minoo and Anahita Saeedi collected the data.

**References**

1. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: A systematic review. JAMA - J Am Med Assoc [Internet] 2015 [cited 2020 Oct 31];313(8):837–46. Available from: https://jamanetwork.com/journals/jama/fullarticle/2130322.
2. Ozieh MN, Bishu KG, Dismuke CE, Egede LE. Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011. BMC Health Serv Res [Internet] 2017 [cited 2020 Oct 18];17(1):1–9. Available from: https://link.springer.com/articles/10.1186/s12913-017-2303-3.
3. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review [Internet]. JAMA - J. Am. Med. Assoc.2019 [cited 2020 Oct 18];322(13):1294–304. Available from: https://jamanetwork.com/journals/jama/fullarticle/2752067.
4. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving global outcomes 2017 clinical practice guideline update [Internet]. Ann. Intern. Med.2018 [cited 2020 Oct 31];168(6):422–30. Available from: http://annals.org/article.aspx?doi=10.7326/M17-2640
5. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41(1):1–12.
6. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries [Internet]. Nephrol. Dial. Transplant.2016[cited 2020Oct18];31(6):868–74. Available from: https://academic.oup.com/ndt/article/31/6/868/1752179.
7. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the Global Burden
of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int [Internet] 2018 [cited 2020 Oct 19];94(3):567–81. Available from: https://www.sciencedirect.com/science/article/pii/S0085253818303181.

8. Tohidi M, Hasheminia M, Mohebi R, Khalili D, Hosseinpanah F, Yazdani B, et al. Incidence of Chronic Kidney Disease and Its Risk Factors, Results of Over 10 Year Follow Up in an Iranian Cohort. PLoS One [Internet] 2012 [cited 2020 Oct 18];7(9):e45304. Available from: https://dx.plos.org/10.1371/journal.pone.0045304.

9. Bouya S, Balouchi A, Rafiemanesh H, Hesarak M. Prevalence of Chronic Kidney Disease in Iranian General Population: A Meta-Analysis and Systematic Review. Ther Apher Dial [Internet] 2018 [cited 2020 Oct 18];22(6):594–9. Available from: http://doi.wiley.com/10.1111/1744-9987.12716.

10. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet [Internet] 2015 [cited 2020 Oct 18];385(9963):117–71. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673614616822.

11. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(9995):743–800.

12. Neovius M, Jacobson SH, Eriksson JK, Elinder CG, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: A population-based cohort study. BMJ Open [Internet] 2014 [cited 2020 Oct 19];4(2):e4251. Available from: http://bmjopen.bmj.com/.

13. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol [Internet] 2008 [cited 2020 Oct 19];3(2):471–80. Available from: www.cjasn.org.

14. Neild GH. Chronic renal failure [Internet]. In: The Scientific Basis of Urology, Second Edition. CRC Press; 2004 [cited 2020 Oct 19]. page 257–64.Available from: https://www.ncbi.nlm.nih.gov/books/NBK535404/.

15. Van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJLF. Impact of age and comorbidity on survival in colorectal cancer. J Gastrointest Oncol [Internet] 2015 [cited 2020 Oct 31];6(6):605–12. Available from: /pmc/articles/PMC4671847/?report=abstract.

16. Balakrishnan N, Ling MH. Expectation maximization algorithm for one shot device accelerated life testing with weibull lifetimes, and variable parameters over stress. IEEE Trans Reliab 2013;62(2):537–51.

17. Wang W, Kececioglu DB. Fitting the Weibull log-linear model to accelerated life-test data. IEEE Trans Reliab 2000;49(2):217–23.

18. Mazucheli J, Louzada F. Lifetime models with nonconstant shape parameters Bias correction View project Applying HD-tDCS for tinnitus patients View project [Internet]. [cited 2020 Oct 31]. Available from: https://www.researchgate.net/publication/254352005.

19. Aghamolaey H, Bagheštani AR, Zayeri F. Application of the Weibull distribution with
a non-constant shape parameter for identifying risk factors in pharyngeal cancer patients. Asian Pacific J Cancer Prev [Internet] 2017 [cited 2020 Oct 31];18(6):1537–42. Available from: /pmc/articles/PMC5697453/?report=abstract.

20. Chan CK. Temperature-Dependent Standard Deviation of Log(Failure Time) Distributions. IEEE Trans Reliab 1991;40(2):157–60.

21. Pham M. Survival Analysis - Breast Cancer. Undergrad J Math Model One + Two 2014;6(1).

22. Bastani P, Ahmad Kiadaliri A. Health-related quality of life after chemotherapy cycle in breast cancer in Iran. Med Oncol [Internet] 2011 [cited 2020 Nov 9];28(SUPPL. 1):70–4. Available from: https://link.springer.com/article/10.1007/s12032-010-9714-x.

23. Lv S, Niu Z, Qu L, He S, He Z. Reliability modeling of accelerated life tests with both random effects and nonconstant shape parameters. Qual Eng [Internet] 2015 [cited 2020 Nov 9];27(3):329–40. Available from: https://www.tandfonline.com/doi/abs/10.1080/08982112.2015.1037393.

24. Baghestani AR, Moghaddam SS, Majd HA, Akbari ME, Nafissi N, Gohari K. Survival analysis of patients with breast cancer using weibull parametric model. Asian Pacific J Cancer Prev 2016;16(18):8567–71.

25. Floege J, Kim J, Ireland E, Chazot C, Druke T, De Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant [Internet] 2011 [cited 2020 Nov 9];26(6):1948–55. Available from: https://academic.oup.com/ndt/article/26/6/1948/1931465.

26. Naves-Daz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martín JL, Rodriguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. the CORES Study. Nephrol Dial Transplant [Internet] 2011 [cited 2020 Nov 8];26(6):1938–47. Available from: https://academic.oup.com/ndt/article/26/6/1938/1931635.

27. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52(3):519–30.

28. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179–87.

29. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol [Internet] 2004 [cited 2020 Nov 10];15(8):2208–18. Available from: https://jasn.asnjournals.org/content/15/8/2208.

30. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70(4):771–80.

31. Reindl-Schwaighofer R, Kainz A, Kammer M, Dumfarth A, Oberbauer R. Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5. PLoS One [Internet] 2017 [cited 2020 Nov 9];12(7):e0181345. Available from: https://dx.plos.org/10.1371/journal.pone.0181345.
32. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 2006;70(2):351–7.
33. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease [Internet]. Nephrol. Dial. Transplant. 2009 [cited 2020 Nov 11];24(5):1506–23. Available from: https://academic.oup.com/ndt/article/24/5/1506/1881102.
34. Riggs JE. Neurologic manifestations of electrolyte disturbances [Internet]. Neurol. Clin. 2002 [cited 2020 Nov 11];20(1):227–39. Available from: http://www.neurologic.theclinics.com/article/S0733861903000604/fulltext.
35. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification [Internet]. J. Intern. Med. 2006 [cited 2020 Nov 11];260(3):192–210. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2796.2006.01692.x.
36. Giachelli CM. Vascular calcification mechanisms [Internet]. J. Am. Soc. Nephrol. 2004 [cited 2020 Nov 11];15(12):2959–64. Available from: https://jasn.asnjournals.org/content/15/12/2959.
37. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol [Internet] 2009 [cited 2020 Nov 11];20(2):388–96. Available from: www.jasn.org.
38. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol [Internet] 2004 [cited 2020 Nov 11];15(8):2208–18. Available from: https://jasn.asnjournals.org/content/15/8/2208.
39. Tsuchihashi K, Takizawa H, Torii TA, Ikeda R, Nakahara N, Yuda S, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: Possible risk of vitamin D3 analog administration in dialysis patients with end-stage renal disease. Nephron [Internet] 2000 [cited 2020 Nov 11];84(1):13–20. Available from: https://www.karger.com/Article/FullText/45533.